ABT Earnings Prediction
The chart below shows how ABT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABT sees a -0.70% change in stock price 10 days leading up to the earnings, and a +1.49% change 10 days following the report. On the earnings day itself, the stock moves by +0.56%. This data can give you a slight idea of what to expect for the next quarter's release.
ABT Key Earning Data
ABT Earnings Analysis
Positive
Earnings Per Share Beat: Abbott Laboratories reported an EPS of $1.09, beating expectations of $1.07.
Sales Growth Analysis: First quarter sales grew 7%, or more than 8% excluding COVID testing sales.
Earnings Per Share Growth: Adjusted earnings per share grew 11% compared to the prior year, finishing at the high end of guidance.
Nutrition Sales Growth: Nutrition sales increased 7%, driven by high single-digit growth in adult nutrition and double-digit growth in US pediatric nutrition.
Brand Loyalty in Parenting: The Similac family of products remains the number one choice for parents in the US, reflecting strong brand loyalty.
Medical Device Sales Growth: Sales in medical devices grew 12.5%, with continuous glucose monitors growing over 20%.
CE Mark Approval Acceleration: Abbott obtained CE Mark for the Volt PFA system earlier than expected, allowing for an expedited launch in Europe.
Product Launch Pipeline: The company is on track to launch over 25 new products over the next three years, indicating a strong pipeline for future growth.
Gross Margin Expansion: Gross margin expanded by 140 basis points compared to the prior year, reflecting effective margin improvement initiatives.
Negative
Diagnostics Segment Sales Decline: Sales in the diagnostics segment declined by 5% due to a significant drop in COVID-19 testing sales, indicating a reliance on pandemic-related revenue that is no longer sustainable.
Laboratory Diagnostics Growth Challenges: Core laboratory diagnostics experienced low single-digit growth, which was negatively impacted by volume-based procurement programs in China, suggesting challenges in international markets.
Currency Impact on Sales: Foreign exchange had an unfavorable year-over-year impact of 2.8% on first quarter sales, highlighting vulnerability to currency fluctuations.
Tariff Impact on Sales Growth: Despite overall sales growth, the company acknowledged that tariffs will have a financial impact, indicating potential future cost pressures.
Transparency Concerns in Earnings: The company did not provide GAAP financial measures on a forward-looking basis for non-GAAP financial measures, which may raise concerns about transparency and predictability of future earnings.
ABT FAQs
How does ABT typically perform around its earnings report dates?
ABT's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a -0.70% change leading up to the report and a +1.49% change in the 10 days following the release.
Is Abbott Laboratories (ABT) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ABT Earning Call Sentiment
Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call Transcript
ABT.N
-2.23%
